Clinical Trials for Recurrent B-Cell Non-Hodgkin Lymphoma

Find clinical trials for recurrent b-cell non-hodgkin lymphoma. Discover research opportunities and treatment options in your area.

9 Active Trials Found

Showing 9 trials on this page

Page 1 of 1

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT ID: NCT05272384

This clinical trial is studying a new treatment for patients with certain types of B-cell lymphoma, specifically those whose cancer has returned after treatment or who have not responded to previou...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States, Birmingham, Alabama, United States +8 more

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

NCT ID: NCT05627245

This clinical trial is investigating the safety and effectiveness of two anti-cancer drugs, tazemetostat and belinostat, for patients with certain types of lymphomas that have come back after treat...

Recruiting

Phase: PHASE1 Type: interventional Locations: New Haven, Connecticut, United States, Oklahoma City, Oklahoma, United States +8 more

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT ID: NCT03147885

This clinical trial is studying a new treatment approach for patients with advanced B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and others. The trial combines a ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Detroit, Michigan, United States, La Jolla, California, United States

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

NCT ID: NCT05453396

This clinical trial is studying a new treatment called loncastuximab tesirine for patients with specific types of B-cell cancers that have either come back after previous treatments or did not resp...

Recruiting

Phase: PHASE2 Type: interventional Locations: Seattle, Washington, United States

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT ID: NCT05507541

This clinical trial is exploring a new treatment option for patients with a type of blood cancer called diffuse large B-cell lymphoma, which has either returned after treatment or has not responded...

Recruiting

Phase: PHASE2 Type: interventional Locations: Rochester, Minnesota, United States, Iowa City, Iowa, United States +1 more

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

NCT ID: NCT05432635

This clinical trial is exploring a new treatment approach for patients with intermediate or high-grade B-cell non-Hodgkin lymphoma, which is a type of cancer affecting the lymphatic system. The stu...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

NCT ID: NCT05801913

This clinical trial is investigating a new treatment approach for patients with intermediate or high-grade B-cell non-Hodgkin lymphoma, a type of blood cancer that can come back after treatment or ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Duarte, California, United States

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

NCT ID: NCT06723457

This clinical trial is exploring the effectiveness of two medications, epcoritamab and lenalidomide, in treating patients with a type of lymphoma called immunodeficiency-related large B-cell lympho...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Chicago, Illinois, United States, Chicago, Illinois, United States

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

NCT ID: NCT04892277

This clinical trial is investigating a new type of treatment called CD19-directed CAR-T cell therapy for patients with specific types of blood cancers, particularly those whose cancer has come back...

Recruiting

Phase: PHASE1 Type: interventional Locations: Rochester, Minnesota, United States

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions